Researchers from the Cincinnati Children's Hospital Medical Center have demonstrated that the tumor necrosis factor-alpha inhibitor etanercept is associated with significant increases in height, weight, and body mass index in children with juvenile idiopathic arthritis, according to a study recently published in Arthritis & Rheumatism.
Researchers from the Cincinnati Children's Hospital Medical Center have demonstrated that the tumor necrosis factor (TNF)-alpha inhibitor etanercept is associated with significant increases in height, weight, and body mass index (BMI) in children with juvenile idiopathic arthritis (JIA), according to a study recently published in Arthritis & Rheumatism. Further, these benefits were apparent regardless of whether methotrexate was used concomitantly.
JIA has been linked to growth retardation in children as a result of the chronic inflammation underlying the disease. Edward Giannini, MD, lead author on this new study stressed, "A realistic treatment goal for JIA patients should include therapy aimed at reducing inflammation in an effort to minimize disease-related disability and growth impairment."
In their paper, researchers reported the results of a 3-year, non-randomized evaluation of anthropometric end points of 594 children with systemic or polyarticular (~90%) JIA treated with etanercept (n=103), methotrexate (n=197), or the combination of both drugs (n=294). Patients receiving the biologic agent etanercept in this registry did so as a twice-weekly dose of 0.4 mg/kg or a once-weekly dose of 0.8 mg/kg. Changes from baseline in anthropometric measurements (mean height, weight, and BMI) were reported using percentiles derived from the Centers for Disease Control and Prevention's standardized growth charts. Their analysis showed that patients receiving etanercept or the combination of etanercept and methotrexate experienced statistically significant increases in height (4.8 and 5.6 percentile points), weight (13.0 and 8.4 percentile points), and BMI (ranges: 9.6–13.8 and 2.1–5.2 percentile points, respectively) from baseline. These improvements in anthropometric end points were seen as early as year 1 of treatment. No effect on these parameters was observed in patients receiving methotrexate alone.
SOURCES
Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis & Rheumatism. 2010;62(11):3259–3264.
Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S. Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004. Arthritis & Rheumatism. 2007;57(8):1439–1445.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More